• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilar Articles for the Week of September 5

Article

Here are the top 5 biosimilar articles for the week of September 5, 2022.

Number 5: In advance of the World Health Organization (WHO) updating its guidelines for biosimilar development, a review article concluded that comparative clinical efficacy and safety studies may not be helpful for the evaluation of biosimilars.

Number 4: In the first article of a 4-part series, The Center for Biosimilars® offers specifics for each of the adalimumab biosimilar products coming in 2023 and explains why the experience in Europe may differ from what’s coming in the United States.

Number 3: Fresenius Kabi announced the FDA approval of its pegfilgrastim biosimilar referencing Neulasta, making it the sixth pegfilgrastim biosimilar to be approved in the United States.

Number 2: Thanks to the success of its adalimumab biosimilar in Canadian and European markets, Alvotech’s revenues reached over $40 million during the first 6 months of 2022, nearly 20 times more than its revenue from the same period in 2021.

Number 1: Ivo Abraham, PhD, chief scientist of Matrix45 and a professor at the University of Arizona, described the pharmacoeconomics of biosimilars and the savings potential for practices and payers if they prioritize greater biosimilar adoption.

To read all of these articles and more, visit centerforbiosimilars.com.

Recent Videos
Here are the top 5 biosimilar articles for the week of March 24, 2025.
Here are the top 5 biosimilar articles for the week of March 17, 2025.
Here are the top 5 biosimilar articles for the week of March 10, 2025.
Here are the top 5 biosimilar articles for the week of March 3, 2025.
Here are the top 5 biosimilar articles for the week of February 24, 2025.
Here are the top 5 biosimilar articles for the week of February 17, 2025.
Travis Brewer, Texas Oncology
Here are the top 5 biosimilar articles for the week of February 10, 2025.
Here are the top 5 biosimilar articles for the week of February 3, 2025.
Josh Canavan, PharmD, head of pharmacy at RazorMetrics
Related Content
© 2025 MJH Life Sciences

All rights reserved.